Neutrophil Clinical Trials

27 recruitingLast updated: May 13, 2026

There are 27 actively recruiting neutrophil clinical trials across 24 countries. Studies span Phase 1, Phase 2, Early Phase 1, Not Applicable, Phase 3, Phase 4. Top locations include Paris, France, New York, New York, United States, London, United Kingdom. Updated daily from ClinicalTrials.gov.


Neutrophil Trials at a Glance

27 actively recruiting trials for neutrophil are listed on ClinicalTrialsFinder across 6 cities in 24 countries. The largest study group is Phase 1 with 12 trials, with the heaviest enrollment activity in Paris, New York, and London. Lead sponsors running neutrophil studies include China Immunotech (Beijing) Biotechnology Co., Ltd., Amgen, and Alexion Pharmaceuticals, Inc..

Browse neutrophil trials by phase

Treatments under study

About Neutrophil Clinical Trials

Looking for clinical trials for Neutrophil? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neutrophil trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neutrophil clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 27 trials

Recruiting
Phase 1Phase 2

CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Marcela V. Maus, M.D.,Ph.D.12 enrolled1 locationNCT07388277
Recruiting
Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled18 locationsNCT06308978
Recruiting
Phase 4

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Amgen300 enrolled76 locationsNCT06072482
Recruiting
Phase 1

Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube

Diffuse Alveolar HemorrhageAntineutrophil Cytoplasmic Antibody Positive Vasculitis
Mayo Clinic6 enrolled1 locationNCT07556484
Recruiting
Phase 2

Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alexion Pharmaceuticals, Inc.75 enrolled78 locationsNCT07160608
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Idiopathic Inflammatory MyopathiesSystemic SclerosisAntineutrophil Cytoplasmic Antibody-associated Vasculitis
Nkarta, Inc.144 enrolled15 locationsNCT06733935
Recruiting
Phase 3

Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGranulomatosis With Polyangiitis
Assistance Publique - Hôpitaux de Paris42 enrolled1 locationNCT04871191
Recruiting
Early Phase 1

Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia

Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaMyeloproliferative Overlap Neoplasms+1 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins18 enrolled1 locationNCT07071155
Recruiting
Phase 1

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus ErythematosusLupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07236762
Recruiting
Phase 1

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Inflammatory MyopathyAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled2 locationsNCT07236801
Recruiting
Phase 1

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Sjogren's Syndrome (SS)+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07123519
Recruiting
Phase 1

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07104721
Recruiting
Early Phase 1

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

Rheumatoid ArthritisSystemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
Changhai Hospital60 enrolled1 locationNCT07246096
Recruiting
Phase 3

Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisEnd Stage Renal Disease
Centre Hospitalier Departemental Vendee136 enrolled58 locationsNCT03323476
Recruiting

Neutrophils to Lymphocytes and Platelets Ratio, Procalcitonin, and Total Leucocytic Count as Indicators of Prognostic Outcome in Septic Patients in the Intensive Care Unit.

Intensive Care UnitPlateletsNeutrophils to Lymphocytes+4 more
Ain Shams University290 enrolled1 locationNCT07200817
Recruiting

Neutrophil to Lymphocyte Ratio and Postdural Headache

Postdural puncture headachePreoperative Neutrophil-to-Lymphocyte Ratio (NLR)
Istinye University821 enrolled1 locationNCT07075874
Recruiting
Phase 1

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Inflammatory Myopathy+5 more
China Immunotech (Beijing) Biotechnology Co., Ltd.12 enrolled1 locationNCT06978647
Recruiting

Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases

Rheumatoid ArthritisCeliac DiseaseSjogren's Syndrome+6 more
Santé Arménie French-Armenian Research Center800 enrolled6 locationsNCT05904301
Recruiting
Not Applicable

Clonal Hematopoiesis and NETs Formation in Venous Thrombosis (CLODETTE)

Clonal Hematopoiesis of Indeterminate PotentialVenous ThrombosesThromboembolic Disease+1 more
University Hospital, Bordeaux150 enrolled7 locationsNCT05711173
Recruiting

Aspirin and Neutrophils in Preeclampsia

PregnancyPreeclampsiaNeutrophil+1 more
Queen Mary University of London60 enrolled1 locationNCT04974892